Tonghua Dongbao Pharmaceutical Co., Ltd. Class ASSE: 600867

"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Termination of an R&D Project and Provision for Asset Impairment

Aug 25, 2026 · Issued by Tonghua Dongbao Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Termination of an R&D Project and Provision for Asset Impairment

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Tonghua Dongbao Pharmaceutical Co., Ltd. Class A

"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Pledge Release and Re-pledge of Shares Held by the Controlling ShareholderAug 13
"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Results of Exercising the Preemptive Rights to Subscribe for the Convertible Corporate Bonds Issued to Unspecified Investors by Xiamen Amoytop Biotech Co., Ltd.Aug 12
"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Release of Pledge and Re-pledge of Controlling Shareholder's SharesJul 29
"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on the U.S. Food and Drug Administration Approval for Marketing of Insulin Aspart InjectionJul 28

All Tonghua Dongbao Pharmaceutical Co., Ltd. Class A news releases